Selective internal radiotherapy	Drug-eluting bead transarterial chemoembolization	Time to progression	1124	1197	with a median TTP of 371 days versus 336 days, respectively (p = 0.5764).
Selective internal radiotherapy	Drug-eluting bead transarterial chemoembolization	Overall survival	1198	1277	Median OS was 592 days for SIRT versus 788 days for TACE patients (p = 0.9271).
Selective internal radiotherapy	Drug-eluting bead transarterial chemoembolization	Time-to-locally-non-treatable-progression	-1	-1	nTTP <TAB> 488 (148/925); 490 ± 114 <TAB> 647 (182/–); 416 ± 83 <TAB> p = 0.9322
Selective internal radiotherapy	Drug-eluting bead transarterial chemoembolization	Time-to-locally-non-treatable-progression	15675	15858	There was no significant difference between groups with respect to TTP (371 days after SIRT versus 336 days after TACE) and nTTP (488 after SIRT versus 647 days after TACE) (Table 3).
Selective internal radiotherapy	Drug-eluting bead transarterial chemoembolization	Time-to-locally-non-treatable-progression	-1	-1	<td align="left">nTTP</td><td align="char" char="(">488 (148/925); 490&nbsp;±&nbsp;114</td><td align="char" char="(">647 (182/–); 416&nbsp;±&nbsp;83</td><td align="left"><NEWLINE> <NEWLINE><italic>p</italic>&nbsp;=&nbsp;0.9322</td>
Selective internal radiotherapy	Drug-eluting bead transarterial chemoembolization	Time to progression	1016	1197	Median progression-free survival (PFS) was 180 days for SIRT versus 216 days for TACE patients (p = 0.6193) with a median TTP of 371 days versus 336 days, respectively (p = 0.5764).
Selective internal radiotherapy	Drug-eluting bead transarterial chemoembolization	Progression-free survival	1016	1123	Median progression-free survival (PFS) was 180 days for SIRT versus 216 days for TACE patients (p = 0.6193)
Selective internal radiotherapy	Drug-eluting bead transarterial chemoembolization	Overall survival	1198	1276	Median OS was 592 days for SIRT versus 788 days for TACE patients (p = 0.9271)
